Key result
Adolescents with major depressive disorder had significantly higher baseline serum levels of resistin compared to healthy controls (26274.16 vs 21678.53 pg/mL, p<0.01).
Why the study?
The study aimed to investigate serum levels of inflammatory markers in adolescents with major depressive disorder using selective serotonin reuptake inhibitors.
Does selective serotonin reuptake inhibitors reduce serum inflammatory markers in adolescents with major depressive disorder?
Observational (n=68)
Open-label
No
Does selective serotonin reuptake inhibitors reduce serum inflammatory markers in adolescents with major depressive disorder?
Absolute Event Rate: 26274.16% vs 21678.53%
p-value: p=<0.01
Adolescents with MDD exhibit elevated baseline resistin levels, and SSRI treatment is associated with parallel reductions in depressive symptoms and specific pro-inflammatory markers (TNF, IL-8, MCP-1).
Elevated resistin may mark inflammation in adolescent MDD; leaves open whether SSRIs modulate it with symptoms.
Objective: This study aimed to investigate the serum levels of inflammatory markers in adolescents with major depressive disorder (MDD) using selective serotonin reuptake inhibitors. Methods: This was an 8-month observational study, involving 30 adolescents with and 38 without (control) MDD diagnosis. Demographic (age and gender) and anthropometric data (weight, height, and calculated body mass index [BMI] z score) were collected. Body composition was assessed with whole-body DXA scan. Depressive and anxiety symptoms were assessed using the Beck Depression and Anxiety Inventories (BDI-II and BAI), respectively. Serum levels of interleukin (IL)-6, IL-8, IL-1β, tumor necrosis factor, monocyte chemoattractant protein-1 (MCP-1), leptin, resistin, and adiponectin were measured using Bio-Plex Multiplex Immunoassays at baseline and after 8 months. Results: At baseline, patients with MDD and controls did not differ in age, gender, BMI z score, and fat mass index (FMI) z score. At follow-up, 58.3% (21/36) of patients with MDD were in full remission. Patients with MDD had higher levels of resistin at baseline (26274.16 pg/mL [16162.68–54252.72]) than controls (21678.53 pg/mL [11221.17–37343.27]; p < 0.01). This difference remained statistically significant after adjustment for sex, age, and FMI z score. No differences in other inflammatory markers were observed between the groups. By follow up, depressive and anxiety symptom severity had decreased significantly in patients with MDD in parallel with a decrease in the serum levels of TNF (p = 0.02), IL-8 (p < 0.01) and MCP-1 (p = 0.04). Among these markers, BDI-II score was positively correlated with serum levels of MCP-1. Conclusion: These results corroborate the view of involvement of peripheral inflammatory mechanisms in the pathophysiology of MDD in adolescents. This trial is registered at ClinicalTrials.gov: NCT02147184.
No takes yet. Share an insight, caveat, or question.
Martins et al. (2021) conducted an observational in Major depressive disorder (MDD) (n=68). Major depressive disorder (MDD) vs. Healthy controls was evaluated on Baseline serum resistin levels (pg/mL) (p=<0.01). Adolescents with major depressive disorder had significantly higher baseline serum levels of resistin compared to healthy controls (26274.16 vs 21678.53 pg/mL, p<0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: